Published Year: 2023
Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis
The global cell and gene therapy biomanufacturing CDMO market - focused on AAV was valued at...
Market Research Report
A quick peek into the report
Global Continuous Bioprocessing Market Report Coverage
|
Global Continuous Bioprocessing Market |
|||
|
Base Year |
2023 |
Market Size in 2023 |
$250.1 Million |
|
Forecast Period |
2023-2033 |
Value Projection and Estimation by 2033 |
$1,639.1 Million |
| CAGR During Forecast Period | 20.68% | Number of Pages |
160 |
| Number of Tables | 79 | Number of Figures |
45 |
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
The chromatography systems and consumables segment players led the market and captured around 32.99% of the market's presence as of 2022. The filtration systems and devices segment, on the other hand, accounted for approximately 28.42% of the market presence in 2022. All the other product types held 38.59% of the market.
Some prominent names established in this market are:
• 3M
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Sartorius AG
• Danaher Corporation
• Corning Incorporated
• Repligen Corporation
• Eppendorf AG
• Entegris, Inc.
• Meissner Filtration Products Inc.
• Kuhner AG
• OmniBRx Biotechnologies Pvt Ltd.
• Bionet
• Solesis Medical
Global Continuous Bioprocessing Market Industry Overview
Introduction of Continuous Bioprocessing
The global continuous bioprocessing market was valued at $250.1 million in 2023 and is expected to reach $1,639.1 million by 2033, growing at a CAGR of 20.68% between 2023 and 2033. The global continuous bioprocessing market is primarily driven by the key objective of intensifying biopharmaceutical production by increasing yield, flexibility, productivity, and product consistency while reducing overall manufacturing costs. The advent of a continuous bioprocessing approach to delivering consistent products has attained significant traction in recent years. While continuous upstream bioprocessing has been around and adapted, today, continuous efforts are underway to integrate downstream bioprocessing into continuous operation.
Market Introduction
The global continuous bioprocessing market is in a nascent stage and exhibits a fragmented landscape owing to the individual influence of both large and emerging players. Large, mid-sized, and emerging companies are actively developing and implementing continuous bioprocessing solutions. While large companies have a notable presence, the landscape is diverse, with various participants, such as Technic, Univercells Technologies, OmniBRx Biotechnologies, and others, contributing to its progress. Another example of Danaher Corporation's acquisition of Cytiva and Pall Lifesciences is among the most noteworthy merger and acquisition deals in the bioprocessing industry. Cytiva, a global leader in the bioprocessing industry, added scaled and differentiated business in upstream consumables and equipment and process chromatography.
Industrial Impact
According to BioPlan’s 18th Annual Report survey, over 40% of respondents reported continuous upstream processing as the second most common system to be evaluated within 2024 in the bioprocessing industry. While the adoption of continuous bioprocessing in approved commercial production has remained limited so far, increased interest from key players to address the challenges involved in the adoption of continuous bioprocessing methods in manufacturing has steered market growth. Some early adopters of continuous bioprocessing include Alvotech, Amgen, BiosanaPharma, Boehringer Ingelheim, Enzene, Genzyme, Transcenta Holdings, Just Biotherapeutics, Novartis, Pfizer, and others.
Market Segmentation:
Segmentation 1: by Product
• Chromatography Systems and Consumables
• Filtration Systems and Devices
• Bioreactors
• Cell Culture Media, Cell Lines, Buffers, and Reagents
• Other Products
Chromatography Systems and Consumables Segment to Dominate the Continuous Bioprocessing Market (by Product Type)
Based on product type, the global continuous bioprocessing market was led by the chromatography systems and consumables segment, which held a 32.99% share in 2022. Chromatography systems refer to equipment used for the separation and purification of biopharmaceuticals or biomolecules in a continuous bioprocessing setup. These systems typically involve columns, pumps, detectors, and other components to separate and analyze different compounds within a mixture.
Segmentation 2: by Process
• Downstream Bioprocess
• Upstream Bioprocess
Upstream Bioprocessing to Witness the Highest Growth between 2023 and 2033
Upstream bioprocessing includes all the steps involved in the preparation and actual production of biological materials. This phase primarily includes the cultivation of cells or microorganisms, which are used to produce the desired bioproducts, such as therapeutic proteins, enzymes, or antibodies. The optimization of upstream processes is crucial for the overall efficiency and cost-effectiveness of biomanufacturing, as it sets the stage for downstream processing. The global continuous bioprocessing market is increasingly adopting these methods to cater to the rising demand for biopharmaceuticals, driven by advancements in biotechnology and the need for more efficient production systems.
Segmentation 3: by Application
• Monoclonal Antibodies
• Vaccines
• Cell and Gene Therapy
• Other Applications
Monoclonal Antibodies Segment to Witness the Highest Growth between 2023 and 2033
Based on application, the continuous bioprocessing market was led by monoclonal antibodies, which held a 63.35% share in 2022. Monoclonal antibodies are immune cells derived from a single parent cell, ensuring genetic uniformity. These antibodies can exhibit a monovalent affinity, indicating their ability to bind to the same specific target.
Segmentation 4: by End User
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations
Pharmaceutical and Biotechnology Companies to Witness the Highest Growth between 2023 and 2033
Pharmaceutical and biotechnology companies refer to organizations involved in the research, development, production, and commercialization of pharmaceutical products and biologics. These companies focus on discovering and manufacturing drugs, vaccines, and therapeutic proteins using various bioprocessing techniques, including continuous bioprocessing. They play a crucial role in advancing healthcare by bringing innovative medicines and biopharmaceuticals to market.
Segmentation 5: by Region
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Netherlands
o Rest-of-Europe
• Asia-Pacific
o Japan
o India
o China
o South Korea
o Australia
o Rest-of-Asia-Pacific
• Latin America
o Brazil
o Mexico
o Rest-of-Latin America
• Rest-of-the-World
The continuous bioprocessing market in the North America region is expected to witness a significant growth rate of 20.43% during the the forecast period, marked by the growing biopharmaceutical sector in the region, digitization of continuous bioprocessing workflow, and increased efficiency and productivity due to continuous bioprocessing. However, the Asia-Pacific region is expected to reach $388.5 million in 2033 from $42.4 million in 2022, at a CAGR of 22.50% during the forecast period 2023-2033.
Recent Developments in the Continuous Bioprocessing Market
• In June 2023, Waters and Sartorius expanded their partnership to develop integrated analytical tools for downstream biomanufacturing following their successful collaboration in upstream processes.
• In September 2023, Sartorius and Repligen Corporation launched an integrated system with Biostat STR and XCell ATF for upstream process intensification.
• In February 2021, 3M Health Care introduced the 3M Polisher ST, a cutting-edge, disposable AEX solution aimed at supplanting the traditional reusable AEX polishing column in the production of biologics drugs. The Polisher ST enhances the biopharmaceutical manufacturing process by diminishing the amount of processing steps, thereby contributing to the enhancement of process efficiency and economic benefits.
Demand – Drivers, Challenges, and Opportunities
Market Demand Drivers:
Growing Demand for Continuous Bioprocessing due to the Flourishing Biopharmaceutical Sector: Continuous bioprocessing is a technique used for manufacturing biopharmaceuticals such as monoclonal antibodies, vaccines, and gene therapies in an uninterrupted, integrated flow, as opposed to traditional batch-by-batch methods. This approach offers several key benefits compared to batch processing. Enhanced productivity and efficiency are achieved because the process is uninterrupted, which leads to the elimination of pauses and waiting periods between different stages of production. Reduced production costs result from needing less equipment, fewer consumables, less media, and lower energy consumption, coupled with increased automation and reduced need for manual oversight.
Market Challenges:
Technological Complexities and Operational Challenges: Despite the advantages of continuous bioprocessing, such as cost reduction, enhanced productivity, improved quality, and greater flexibility, its adoption has been gradual. Batch processing, being efficient and familiar, remains preferred, whereas continuous processing is often perceived as more intricate and prone to issues.
Market Opportunities:
Numerous Proposed Technologies in Global Continuous Bioprocessing: The global continuous bioprocessing market is a rapidly evolving sector driven by technological advancements that aim to enhance efficiency, reduce costs, and increase the speed of biopharmaceutical production. Continuous bioprocessing is a method that allows for the constant feeding of substrates and removal of products, which contrasts with traditional batch processing. This continuous approach can lead to improvements in productivity and product quality, as well as more flexible and scalable processes. Key technological advancements within this sector, reflecting on how these innovations address industry challenges and contribute to the market's growth, have been explored.
Analyst’s Thoughts
According to Swati Sood, Principal Analyst – BIS Research, “The continuous bioprocessing market is witnessing transformative growth, driven by the biopharmaceutical industry's push for more efficient, cost-effective, and flexible manufacturing solutions. Continuous bioprocessing, owing to its potential to streamline operations and enhance product quality, is rapidly moving from an innovative concept to an essential strategy for companies aiming to stay competitive in a fast-evolving landscape. The adoption of continuous bioprocesses is not just a technological upgrade but a strategic pivot toward sustainability, agility, and regulatory compliance. Key trends within the market include the integration of advanced analytics, the rise of single-use technologies, and the emphasis on partnerships to accelerate technological advancements and adoption."
Global Continuous Bioprocessing Market
Focus on Application, Product, Process, End User, Region, and Competitive Landscape - Analysis and Forecast, 2023-2033
Some Faq's
Frequently Asked Questions
Ans: Continuous bioprocessing can be defined as the segment of the biopharmaceutical industry that focuses on the production and manufacturing of biologics, vaccines, and pharmaceuticals using continuous and uninterrupted processes, which are opposite to traditional batch processing. This market includes bioreactors, chromatography systems, consumables, filtration systems and devices, and other related products involved in the streamlined and continuous production of biopharmaceutical products such as monoclonal antibodies, vaccines, cell and gene therapy and other applications, with the aim of improving efficiency, reducing production costs, and accelerating the delivery of vital medical treatments to patients.
Ans: As companies strive to strengthen their market positions, they are adopting a variety of innovative strategies. These strategies not only address the inherent complexities of bioprocessing but also align with regulatory standards and meet the growing demand for biologics. Collaborations between biopharmaceutical companies and technology providers are becoming more common. These partnerships aim to leverage the strengths of each party to accelerate the development and commercialization of continuous bioprocessing solutions. For example, collaborations can enable access to equipment and expertise in process optimization, thereby reducing the time and cost associated with bringing biologics to market.
The following are the USPs of this report:
• Market regulations and key trends in the continuous bioprocessing market
• Market map for key players, along with the developments in manufacturing facilities
• Market dynamic analysis of the opportunities, trends, and challenges in the market
• Supply chain and value chain for continuous bioprocessing market
• Next frontiers in the continuous bioprocessing market
Ans: The continuous bioprocessing market report is a critical resource for a broad spectrum of stakeholders within the biopharmaceutical industry and related sectors. Its insights into market trends, technological advancements, regulatory landscapes, and strategic approaches to manufacturing can guide decision-making and strategic planning. The report is particularly valuable for:
• Biopharmaceutical Companies
• Equipment and Technology Providers
• Academic and Research Institutions
• Supply Chain and Logistics Providers
Similar Product
You may also like
Published Year: 2023
Biomanufacturing Viral Detection and Quantification Market - A Global and Regional Analysis: Focus o
The global biomanufacturing viral detection and quantification market was valued at $474.3...